Antibodies, including monoclonal, human, primate, rodent, mammalian, chimeric, humanized and CDR-grafted antibodies, and antigen binding fragments and antigen binding derivatives thereof, bind to CD47 protein, particularly human CD47, modulate, e.g., inhibit, block, antagonize, neutralize or otherwise interfere with CD47 expression, activity and/or signaling, including inhibiting CD47 and SIRP α interaction； do not cause a significant level of hemagglutination of human red blood cells. The antibody may not enhance RBC phagocytosis.包括單株抗體、人類抗體、靈長類動物抗體、囓齒動物抗體、哺乳動物抗體、嵌合抗體、人類化抗體及CDR移植抗體在內之抗體以及其抗原結合片段及抗原結合衍生物結合至CD47蛋白，尤其人類CD47，調控，例如抑制、阻斷、拮抗、中和或以其他方式干擾CD47之表現、活性及/或信號傳導，包括抑制CD47與SIRP α之相互作用；不引起人類紅血球之顯著血球凝集水準。該抗體可能不增強RBC之吞噬作用。
